Last updated: September 5, 2026
The fixed-dose combination of amlodipine besylate, hydrochlorothiazide and olmesartan medoxomil is marketed in the United States as Tribenzor by Daiichi Sankyo. It combines a calcium-channel blocker, a thiazide diuretic and an angiotensin II receptor blocker for hypertension. The product entered a mature, genericized antihypertensive market and never achieved the commercial scale of its individual components or the broader Benicar franchise.
Tribenzor received U.S. approval in 2010. Its economic trajectory was shaped by four factors: rapid substitution toward lower-cost generic antihypertensives, loss of exclusivity for olmesartan-based products, limited differentiation from separate-pill therapy, and the absence of biologic-style manufacturing or regulatory barriers. The product remains commercially relevant as a treatment option, but its branded revenue potential is limited.
What is the product and how does it compete?
Tribenzor contains three established antihypertensive ingredients:
| Component |
Drug class |
Commercial role |
| Amlodipine besylate |
Dihydropyridine calcium-channel blocker |
Low-cost, widely substituted generic |
| Hydrochlorothiazide |
Thiazide diuretic |
Long-established generic diuretic |
| Olmesartan medoxomil |
Angiotensin II receptor blocker |
The differentiated component and former Benicar active ingredient |
The product is available in four U.S. strength combinations:
| Amlodipine |
Hydrochlorothiazide |
Olmesartan medoxomil |
| 5 mg |
12.5 mg |
20 mg |
| 10 mg |
12.5 mg |
40 mg |
| 5 mg |
25 mg |
40 mg |
| 10 mg |
25 mg |
40 mg |
Tribenzor is positioned for patients whose blood pressure is inadequately controlled on dual therapy. Its principal commercial advantage is convenience: three active ingredients in one tablet. Its disadvantages are higher cost than separate generic tablets, limited dose flexibility and the inability to independently titrate each component.
The competitive set includes generic amlodipine, hydrochlorothiazide, olmesartan, losartan, valsartan, irbesartan and combinations such as amlodipine/valsartan, amlodipine/olmesartan and olmesartan/hydrochlorothiazide. Fixed-dose combinations from Novartis, Daiichi Sankyo, Mylan/Viatris, Teva and other manufacturers compete for the same adherence and convenience segment.
When did Tribenzor receive FDA approval?
The FDA approved Tribenzor on July 23, 2010, under NDA 200796. The approval covered adults with hypertension requiring treatment with all three components or patients not adequately controlled on two of the components. The FDA label identifies the product as a once-daily oral tablet [1].
Tribenzor followed Daiichi Sankyo’s earlier olmesartan products:
| Product |
Ingredients |
U.S. commercial significance |
| Benicar |
Olmesartan medoxomil |
Core ARB franchise |
| Benicar HCT |
Olmesartan medoxomil/hydrochlorothiazide |
Dual-combination product |
| Azor |
Amlodipine besylate/olmesartan medoxomil |
Dual-combination product |
| Tribenzor |
Amlodipine besylate/hydrochlorothiazide/olmesartan medoxomil |
Triple-combination product |
The development strategy extended the Benicar franchise into progressively more complex combinations. That strategy supported prescribing continuity but did not create a durable premium once the underlying ingredients became generic.
When did olmesartan and the combination lose exclusivity?
Olmesartan medoxomil’s core U.S. composition-of-matter protection expired in the middle of the 2010s. Generic olmesartan products subsequently entered the market, placing downward pressure on Benicar, Benicar HCT and Azor. Amlodipine and hydrochlorothiazide had already been generic for many years.
Tribenzor’s commercial protection was therefore weaker than the protection of a new chemical entity. Its active ingredients were individually known, and the principal innovation was the fixed-dose combination. Any surviving combination patent could delay a particular generic product, but it could not prevent physicians from prescribing the three generic ingredients separately.
The practical exclusivity timeline was:
| Period |
Event |
Commercial effect |
| 2010 |
FDA approval of Tribenzor |
Launch of branded triple therapy |
| 2011-2013 |
Early branded adoption |
Expansion of the Benicar combination portfolio |
| 2015-2016 |
Generic olmesartan availability |
Accelerated erosion of the broader franchise |
| Late 2010s |
Generic competition to triple-combination products |
Reduced branded pricing power |
| 2020s |
Mature generic market |
Volume remains, but branded revenue is limited |
The FDA’s Orange Book is the controlling source for active listed patents, pediatric exclusivity and reference-product information. Orange Book status should be assessed by product and NDA because patent listings can change through expiration, delisting or administrative updates [2].
What patents protect amlodipine, hydrochlorothiazide and olmesartan?
The patent estate is materially weaker today than during the Benicar franchise’s peak.
Composition-of-matter protection
Amlodipine and hydrochlorothiazide are long-established generic molecules. Their composition patents expired well before Tribenzor launched. Olmesartan medoxomil’s original composition protection also expired before the current market reached maturity.
This means the commercial barrier is not access to the active ingredients. Generic manufacturers can source all three ingredients through established pharmaceutical supply chains.
Formulation and fixed-dose patents
The remaining patent value historically centered on:
- Fixed-dose combinations of the three ingredients.
- Tablet composition and manufacturing processes.
- Dose-ratio combinations.
- Pharmaceutical formulations designed to improve stability or dissolution.
- Method-of-use claims covering treatment of hypertension.
These claims can affect an ANDA applicant’s launch strategy, but they have limited power against separate-pill substitution. A generic manufacturer can also challenge listed patents through a Paragraph IV certification or wait for patent expiration.
Method-of-use patents
Method-of-use patents may cover treatment of hypertension using particular combinations, doses or patient populations. Their value depends on whether the patented indication is commercially important and whether prescribing, labeling or induced-infringement issues can be established.
For a broad hypertension product, method-of-use protection is generally less durable than composition protection. Physicians may use the active ingredients independently, and generic labels can omit a protected indication under a section viii carve-out where legally available.
How many patents cover Tribenzor and what is the Orange Book status?
Tribenzor is an NDA drug rather than a biologic. Its Orange Book analysis requires review of the current entries associated with NDA 200796 and any approved strengths. The relevant questions are:
- Which patents remain listed?
- Which patents have expired?
- Are any pediatric exclusivity periods active?
- Have generic applicants filed Paragraph IV certifications?
- Are approved generics therapeutically substitutable across all four strengths?
The commercial significance of any remaining listing is limited by three factors:
- The individual ingredients are generic.
- Physicians can use separate tablets.
- Multiple manufacturers can compete through alternative fixed-dose combinations.
The principal patent risk for a generic entrant is therefore launch timing and litigation cost, not long-term market exclusion.
Which companies are challenging the product?
The generic competitive field includes major generic manufacturers and regional suppliers of olmesartan-based combinations. Public market dynamics indicate broad generic competition rather than dependence on a single challenger. Relevant participants in the U.S. hypertension market include Teva, Mylan/Viatris, Torrent Pharmaceuticals, Lupin, Zydus, Dr. Reddy’s Laboratories and other ANDA sponsors.
The absence of a biologic reference product means there is no biosimilar pathway. Generic versions proceed through the abbreviated new drug application system, with therapeutic equivalence determined through FDA requirements for pharmaceutical equivalence and bioequivalence.
A Paragraph IV challenge could target a listed formulation or combination patent. A successful challenge could enable an earlier launch. A non-infringement, invalidity or unenforceability determination could remove the principal remaining barrier to generic entry.
What patent litigation and settlement agreements affect Tribenzor?
The major litigation exposure occurred during the broader olmesartan franchise’s transition from branded to generic competition. Patent disputes involving Benicar, Benicar HCT, Azor or Tribenzor could influence launch timing, but litigation affecting the underlying olmesartan franchise has greater commercial importance than litigation involving the triple-combination product alone.
No settlement should be treated as creating broad market exclusivity unless its terms establish a defined launch date, authorized generic restrictions, license rights or supply obligations. In pharmaceutical settlements, the relevant commercial provisions are often more important than the existence of litigation itself.
For diligence purposes, the key records are:
- FDA Orange Book patent listings.
- ANDA litigation complaints under the Hatch-Waxman Act.
- District court judgments.
- Federal Circuit decisions.
- FTC review of reverse-payment arrangements.
- Approved labeling and any patent-use-code records.
What is the financial trajectory of Tribenzor?
Daiichi Sankyo has not historically reported Tribenzor as a consistently separate material revenue line. Revenue was generally incorporated into broader U.S. cardiovascular or Benicar-related reporting. The product’s financial trajectory can therefore be analyzed through franchise economics rather than a reliable standalone sales series.
Launch phase: 2010-2013
Tribenzor benefited from:
- The established Benicar prescriber base.
- Growth in fixed-dose combination prescribing.
- Reimbursement for branded antihypertensive therapy.
- Convenience for patients requiring three agents.
The product’s early revenue was supported by brand pricing and cross-selling within the Benicar portfolio. Uptake was constrained by payer pressure and the availability of inexpensive separate-pill regimens.
Erosion phase: 2014-2018
The key inflection point was generic olmesartan. Once generic ARB therapy became available, branded Benicar products lost pricing power. Tribenzor was exposed to the same erosion because two of its three components were already generic and the third became generic during the product’s commercial life.
Payers increasingly encouraged:
- Generic olmesartan.
- Generic amlodipine.
- Generic hydrochlorothiazide.
- Separate-pill combinations.
- Lower-cost ARB combinations.
The product’s net price, prescription share and formulary position declined.
Mature phase: 2019 onward
Tribenzor operates in a low-growth, price-sensitive market. Remaining demand is driven by:
- Patients stabilized on the product.
- Physicians prioritizing one-pill adherence.
- Patients who tolerate olmesartan better than alternative ARBs.
- Pharmacies and plans that retain a covered generic or branded source.
- Prescribers who prefer the triple-combination dose architecture.
Revenue is unlikely to return to the product’s pre-generic level. Volume may persist while value declines because generic substitution, rebates and payer restrictions reduce realized price.
How does Tribenzor compare with competing antihypertensive combinations?
| Product class |
Main advantage |
Main disadvantage |
Commercial pressure |
| Tribenzor |
Three drugs in one tablet |
Limited dose flexibility and generic competition |
Very high |
| Amlodipine/olmesartan |
Two-drug convenience |
Requires separate diuretic if needed |
High |
| Olmesartan/hydrochlorothiazide |
Familiar ARB/diuretic combination |
Requires separate calcium-channel blocker |
High |
| Amlodipine/valsartan |
Broad prescriber familiarity |
Valsartan is generic |
High |
| Separate generic tablets |
Lowest cost and maximum dose flexibility |
Higher pill burden |
Very high |
| Newer branded triple combinations |
Potential formulation or adherence differentiation |
Premium pricing |
Moderate to high |
Tribenzor’s strongest competitive attribute is adherence convenience. Its weakest attribute is the limited ability to justify a branded premium after generic versions of all three components are available.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest. The product is a conventional oral solid dosage form, and the active ingredients are widely manufactured. The main technical requirements are:
- Control of tablet uniformity across three ingredients.
- Stability and impurity management.
- Bioequivalence across each strength.
- Manufacturing process validation.
- Packaging that protects product stability.
- Regulatory support for all marketed dose combinations.
The principal barriers are regulatory execution and commercial scale, not molecule synthesis. A generic manufacturer must produce all relevant strengths, demonstrate bioequivalence and manage supply economics in a crowded market.
What generic launch scenarios exist?
Three launch scenarios are commercially plausible:
Full-strength generic entry
A manufacturer launches all four strengths after resolving patent and regulatory issues. This creates the fastest erosion of branded volume and can establish pharmacy substitution.
Partial-strength entry
A manufacturer initially launches the highest-volume strengths, often the 5/25/40 mg or 10/25/40 mg configurations, then expands. This limits early manufacturing investment but may reduce formulary access.
Separate-pill substitution
Payers and physicians bypass the fixed-dose product with generic olmesartan, amlodipine and hydrochlorothiazide. This scenario can reduce Tribenzor demand even without a directly substitutable generic triple tablet.
The third scenario is the most important strategic risk because it does not depend on a single patent litigation outcome.
What revenue exposure does the product create for Daiichi Sankyo?
Tribenzor is unlikely to represent material current revenue exposure relative to Daiichi Sankyo’s oncology portfolio and other higher-value products. Its historical value was strategic: it extended the life cycle of olmesartan and increased the number of branded treatment configurations available to prescribers.
The product’s residual value comes from:
- Existing prescription continuity.
- Low incremental development cost.
- Potential licensing or authorized-generic arrangements.
- Manufacturing or portfolio rationalization.
- Cash flow from mature demand where pricing remains adequate.
The main downside is margin compression. A mature cardiovascular combination can retain prescription volume while contributing little gross profit after generic substitution and channel discounts.
What is the regulatory status and biosimilar risk?
Tribenzor is an FDA-approved small-molecule prescription drug. It is not a biologic and has no biosimilar risk. Competition proceeds through the ANDA pathway, not through the Public Health Service Act biosimilar pathway.
The regulatory risks are standard for a mature oral combination:
- ANDA approvals for generic equivalents.
- Manufacturing observations or supply interruptions.
- Labeling revisions.
- Postmarketing adverse-event findings.
- Product recalls.
- Changes in Orange Book listings.
The FDA label identifies warnings and precautions associated with hypotension, renal impairment, hyperkalemia, fetal toxicity and electrolyte abnormalities, reflecting the known risks of the three component classes [1].
Key Takeaways
- Tribenzor is the U.S. brand for amlodipine besylate, hydrochlorothiazide and olmesartan medoxomil.
- FDA approval occurred in 2010 under NDA 200796.
- Its commercial strategy extended Daiichi Sankyo’s Benicar franchise into triple therapy.
- Amlodipine and hydrochlorothiazide were already generic when Tribenzor launched.
- Generic olmesartan caused the major erosion of the broader franchise during the mid-to-late 2010s.
- The product has limited remaining pricing power because all three ingredients are generic.
- Fixed-dose, formulation and method-of-use patents may affect launch timing but cannot prevent separate-pill substitution.
- Tribenzor has no biosimilar risk because it is a small-molecule drug.
- Current commercial value is concentrated in adherence convenience, residual prescription volume and potential low-cost generic supply.
- The principal launch risk for a generic competitor is market pricing, not access to the active ingredients.
FAQs
Is Tribenzor still commercially important?
It remains clinically relevant as a once-daily triple antihypertensive, but its branded financial importance is substantially lower than during the Benicar franchise’s protected period.
Are generic versions of Tribenzor available?
Generic competition can arise through approved ANDAs for the fixed-dose combination and through separate generic tablets. The commercial impact of separate-pill substitution is significant even where a direct triple-combination generic is limited.
Is olmesartan the main value driver in the combination?
Yes. Amlodipine and hydrochlorothiazide are long-established generic ingredients. Olmesartan historically supplied the branded differentiation and franchise value.
Can a patent on Tribenzor block generic olmesartan?
No. A combination patent cannot generally prevent lawful sale of generic olmesartan as a standalone product. It may affect a specific fixed-dose combination product or labeled use.
What is the main investment risk associated with Tribenzor?
The main risk is continued value erosion from generic substitution, payer pressure and low-cost separate-pill therapy. The product does not have the exclusivity profile or pricing power of a protected innovative medicine.
References
-
U.S. Food and Drug Administration. (2024). Tribenzor: Prescribing information. Daiichi Sankyo, Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Daiichi Sankyo Company, Limited. (2010-2024). Annual reports and integrated reports. https://www.daiichisankyo.com/investors/
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and generic drug regulatory information. https://www.fda.gov/drugs/generic-drugs
